Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.65 |
| ▸ | JAK2 | O60674 | 2/20 | 0.61 |
| ▸ | JAK1 | P23458 | 2/20 | 0.61 |
| ▸ | TYK2 | P29597 | 2/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519295 | 0.82 | PTGER4 (0.61) | HDAC6HDAC1HDAC8JAK2JAK1 | |
| SCHEMBL21975920 | 0.81 | HDAC6 (0.95) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL6511758 | 0.80 | HDAC1 (0.80) | HDAC6HDAC1HDAC8 | |
| SCHEMBL6509075 | 0.80 | HDAC1 (0.80) | HDAC6HDAC1HDAC8 | |
| SCHEMBL18229537 | 0.79 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL15314762 | 0.77 | ALDH1A1 (0.73) | HDAC6HDAC1HDAC8 | |
| SCHEMBL29411911 | 0.77 | ALDH1A1 (0.73) | HDAC6HDAC1HDAC8 | |
| SCHEMBL3578681 | 0.77 | HDAC1 (1.00) | HDAC6HDAC1HDAC8EHMT2EHMT1 | |
| SCHEMBL28503563 | 0.76 | ALDH1A1 (0.63) | JAK2JAK1TYK2JAK3EHMT2 | |
| SCHEMBL5564854 | 0.76 | HDAC8 (0.66) | HDAC6HDAC1HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | claimed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137234-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC11 | HDAC6 10/4885HDAC1 1/4885HDAC8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.